Myriad Genetics price target lowered to $11 from $13 at BofA
BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad ...
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Veeva Systems (VEEV)
Analysts are pulling back from the Healthcare sector as 2 experts expressed today bearish sentiments on Myriad Genetics (MYGN – Research ...
Hosted on MSN6d
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Myriad Genetics, Inc. MYGN reported fourth-quarter 2024 adjusted earnings of 3 cents per share, which came in line with the ...
StockStory.org on MSN6d
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported ...
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales ...
New York State Common Retirement Fund Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN)
New York State Common Retirement Fund boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by ...
Q1 EPS Estimates for Myriad Genetics Reduced by Analyst
Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P.
Nasdaq4d
Myriad Genetics is Now Oversold (MYGN)
In trading on Thursday, shares of Myriad Genetics, Inc. (Symbol: MYGN) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $11.12 per share. By ...